Outcomes of intensive care patients with acute small-vessel vasculitis: a 23-year single-centre experience

Clicks: 10
ID: 329432
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #331 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Objectives Patients with fulminant small-vessel vasculitis (SVV) may require intensive care unit (ICU) admission, where mortality is high. We describe outcomes and prognostic factors in ICU patients with ANCA-associated vasculitis (AAV) and anti-glomerular basement membrane (anti-GBM) disease over a 23-year period. Methods Patients admitted with acute manifestations of new or flaring AAV or anti-GBM disease were identified from our hospital ICU database (1999-2022). Patients treated solely in high-dependency areas were excluded. Primary outcomes were mortality at 30 and 90 days and development of end-stage kidney disease (ESKD). A matched case-control analysis (1:4) adjusted for age, gender, APACHE II score and admission year was performed for a patient subgroup. Results 85 cases (82% AAV, 15% anti-GBM) were identified, 80% newly diagnosed. Median APACHE II score was 19. Ventilatory support and continuous venovenous haemodiafiltration were required in 92% and 66% of cases, respectively. 30-day and 90-day mortality rates were 15% and 26%, respectively. Among 90-day survivors, 17 (28%) developed new ESKD. Vasculitis treatments included cyclophosphamide (59%), rituximab (53% of AAV patients) and plasma exchange (71%). These treatments were associated with 90-day and long-term survival. Treatment for vasculitis post-2008 was associated with 90-day and long-term survival, which was not mirrored in ICU controls. This coincided with improvements to the vasculitis service and therapeutic strategies. Conclusions This single-centre study reports ICU outcomes for patients with fulminant SVV over 23 years. 30 and 90-day ICU mortality were comparable with other reported values. Improvement in mortality was associated with changes in vasculitis treatment protocols.
Reference Key
openalex_W7214064164 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Arden Dierker Viik, Yiwang Xu, Dominic McGovern, Seerapani Gopaluni, Michael Chen-Xu, James Varley, Lisa Willcocks, Rona Smith, Iftach Sagy, David Jayne, Rachel Jones
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag531
URL
https://doi.org/10.1093/rheumatology/keag531
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.